Back to Careers

Juvena gets FDA Orphan Drug nod for muscle regeneration therapy

Back to Careers

Juvena’s JUV-161 awarded US orphan drug designation for myotonic dystrophy type 1

Back to Careers

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1

Back to Careers

Juvena Therapeutics is recognized in Biospace’s Top 30 list, “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year”

Back to Careers

The Science of Longevity: Stopping Aging at the Cellular Level to Prevent Disease and Improve Quality of Life” as an invited panelist for the 2023 Biotech Showcase.

Back to Careers

Juvena’s CEO, Dr. Hanadie Yousef is recognized by FierceBiotech in their 2023 shortlist of 10 of the fiercest women in life sciences.

Back to Careers

CEO Dr. Hanadie Yousef discussed the convergence of AI, healthcare, and longevity in early November in Paris at JPM 40×40 as an invited speaker amongst a curated group of global business leaders across all sectors.

Back to Careers

Dr. Hanadie Yousef attends the Global Healthspan Summit in Riyadh, Saudi Arabia, organized by the Hevolution Summit as an invited speaker showcased on their Entrepreneurship Spotlight panel

Back to Careers

CEO, Dr. Yousef presented Juvena’s approach to mining the regenerative secretomes of human pluripotent stem cells to identify and develop novel disease-modifying biologics that promote tissue regeneration and repair in order to rejuvenate lives as the 14th annual drug discovery strategic summit this year.